EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Activity of cefiderocol against Pseudomonas aeruginosa from the USA and Europe (2020–2023) with difficult-to-treat resistance phenotype, including those nonsusceptible to recently developed β-lactam/β-lactamase inhibitor combinations: results from the SENTRY antimicrobial surveillance program

John H Kimbrough iD, Maura H Karr, Sean T Nguyen, Boudewijn L M DeJonge iD, Chris Longshaw iD, Miki Takemura iD, Yoshinori Yamano, Mariana Castanheira iD, Rodrigo E Mendes iD

Microbiology Spectrum · 04.11.2025 · 13 (11)

DOI: 10.1128/spectrum.02079-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, erschienen am 04.11.2025. Verfasst von John H Kimbrough und 8 weiteren Autor:innen. Beteiligte Einrichtung: Element Iowa City (JMI Laboratories), North Liberty, Iowa, USA. Hauptthemen laut MEDLINE: Pseudomonas aeruginosa, Anti-Bacterial Agents, Cephalosporins, beta-Lactamase Inhibitors. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cefiderocol and the β-lactam/β-lactamase inhibitor (BL-BLI) combinations ceftazidime-avibactam (CAZ-AVI), imipenem-relebactam (IMI-REL), and ceftolozane-tazobactam (TOL-TAZ) are recommended for the treatment of difficult-to-treat resistance (DTR) Pseudomonas aeruginosa by IDSA guidelines. The activity of cefiderocol and the three BL-BLI combinations described above was examined against DTR P. aeruginosa and molecularly characterized subsets collected from the USA and Europe (2020–2023). Approximately 4% of isolates showed a DTR phenotype, and cefiderocol remained active against 98.1% (CLSI breakpoint) of these isolates, whereas the three BL-BLI combinations had susceptibilities of 52.3%–56.0%. A total of 63% of DTR isolates were nonsusceptible to ≥1 of these BL-BLI combinations, and cefiderocol was active against ≥95.5% (CLSI) of these isolates, regardless of the nonsusceptible phenotype(s) to these combinations. In contrast, susceptibilities of the BL-BLI combinations varied from 0.0% to 30.3%. Almost 20% of DTR isolates carried carbapenemases, mostly metallo-β-lactamases, represented by 14 different STs from 15 countries. Cefiderocol had MIC 50/90 of 0.25/2 mg/L against these carbapenemase-carrying DTR isolates and 97.3% (CLSI) of the isolates were susceptible to cefiderocol, whereas

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pseudomonas aeruginosaAnti-Bacterial AgentsCephalosporinsbeta-Lactamase InhibitorsPseudomonas InfectionsEuropeUnited StatesMicrobial Sensitivity TestsHumansDrug CombinationsCeftazidimeCefiderocolAzabicyclo CompoundsTazobactamPhenotypebeta-LactamasesDrug Resistance, Multiple, Bacterial

Stichwörter der Autor:innen

DTRIDSAMBLcarbapenem resistanceguidelines

Substanzen

Anti-Bacterial AgentsCephalosporinsbeta-Lactamase InhibitorsDrug CombinationsCeftazidimeCefiderocolavibactam, ceftazidime drug combinationAzabicyclo CompoundsTazobactamceftolozane, tazobactam drug combination

Autor:innen und Institutionen

  • Element Iowa City (JMI Laboratories), North Liberty, Iowa, USA.
  • Shionogi Inc., Florham Park, New Jersey, USA.
  • Shionogi B.V., London, United Kingdom.
  • Shionogi & Co., Ltd., Osaka, Japan.

ORCID-Profile: John H Kimbrough, Boudewijn L M DeJonge, Chris Longshaw, Miki Takemura, Mariana Castanheira, Rodrigo E Mendes

Zitieren

APA

Kimbrough, J. H., Karr, M. H., Nguyen, S. T., DeJonge, B. L. M., Longshaw, C., Takemura, M., Yamano, Y., Castanheira, M., & Mendes, R. E. (2025). Activity of cefiderocol against Pseudomonas aeruginosa from the USA and Europe (2020–2023) with difficult-to-treat resistance phenotype, including those nonsusceptible to recently developed β-lactam/β-lactamase inhibitor combinations: results from the SENTRY antimicrobial surveillance program. Microbiology Spectrum, 13(11). https://doi.org/10.1128/spectrum.02079-25

Vancouver

Kimbrough JH, Karr MH, Nguyen ST, DeJonge BLM, Longshaw C, Takemura M, et al. Activity of cefiderocol against Pseudomonas aeruginosa from the USA and Europe (2020–2023) with difficult-to-treat resistance phenotype, including those nonsusceptible to recently developed β-lactam/β-lactamase inhibitor combinations: results from the SENTRY antimicrobial surveillance program. Microbiology Spectrum. 2025;13(11). doi:10.1128/spectrum.02079-25

BibTeX
@article{Kimbrough2025,
  author = {Kimbrough, John H and Karr, Maura H and Nguyen, Sean T and DeJonge, Boudewijn L M and Longshaw, Chris and Takemura, Miki and Yamano, Yoshinori and Castanheira, Mariana and Mendes, Rodrigo E},
  title = {Activity of cefiderocol against Pseudomonas aeruginosa from the USA and Europe (2020–2023) with difficult-to-treat resistance phenotype, including those nonsusceptible to recently developed β-lactam/β-lactamase inhibitor combinations: results from the SENTRY antimicrobial surveillance program},
  journal = {Microbiology Spectrum},
  year = {2025},
  volume = {13},
  number = {11},
  doi = {10.1128/spectrum.02079-25}
}
Kostenlos starten →